每经AI快讯，众生药业（002317.SZ）12月16日在投资者互动平台表示，公司会充分结合实际，积极拥 抱新技术，探索新技术的无限可能。公司昂拉地韦片治疗12~17岁青少年单纯性甲型流感患者和昂拉地 韦颗粒治疗2~11岁儿童单纯性甲型流感患者两项III期临床试验正在积极推进中，目前已完成全部参与 者入组工作。公司争取早日完成相关研究，申报药物上市，为广大患者提供更多治疗选择。 （文章来源：每日经济新闻） ...

（文章来源：每日经济新闻） 每经AI快讯，众生药业（002317.SZ）12月16日在投资者互动平台表示，公司昂拉地韦颗粒III期临床试 验正在积极推进中，目前已完成全部参与者入组工作。公司争取早日完成相关研究，申报药物上市，为 广大患者提供更多治疗选择。公司将严格按照相关规则及要求履行决策程序和信息披露义务。 ...

每经AI快讯，有投资者在投资者互动平台提问：昂拉地韦青少年三期临床和颗粒的三期临床，设计试 验周期是多长时间？ （记者 胡玲） 众生药业（002317.SZ）12月10日在投资者互动平台表示，公司组织昂拉地韦片治疗12~17岁青少年单纯 性甲型流感患者和昂拉地韦颗粒治疗2~11岁儿童单纯性甲型流感患者的两项III期临床试验，两项III期 临床研究设计为每日用药1次，共服药5天，目前均已完成所有参与者入组。公司将有序推进项目开发工 作。 ...

Core Insights - The Hong Kong and A-share innovative drug sectors have shown significant weekly performance, with notable increases in specific stocks such as Haiwang Bio and Kangfang Biotech, indicating a positive trend in the market [2][4][5]. Market Performance - The pharmaceutical and biotechnology index rose by 1.50%, outperforming the Shanghai Composite Index by 0.10 percentage points, marking two consecutive weeks of gains [4]. - The innovative drug sector (BK1106) saw a weekly increase of 4.26%, while the Hang Seng Healthcare Index (HSCICH) rose by 3.64% and the Hong Kong innovative drug ETF (513120) increased by 4.00% [4]. Stock Highlights - Haiwang Bio experienced a remarkable weekly increase of 38.21%, while Kangfang Biotech led with a 14.86% rise [2]. - The focus on children's antiviral drugs is highlighted by the initiation of Phase III trials for the drug Anladiwei by Zhongsheng Pharmaceutical, targeting a critical market need [12][13]. IPO Developments - Lingke Pharmaceutical has filed for an IPO in Hong Kong, focusing on innovative drugs for autoimmune and inflammatory diseases, with its lead candidate LNK01001 facing intense competition from existing JAK inhibitors [6][7]. - The company reported R&D expenditures of approximately 186 million yuan, 223 million yuan, and 121 million yuan for the years 2023, 2024, and the first nine months of 2025, respectively [7]. Clinical Trials - A total of 110 clinical trial registrations were disclosed by the National Medical Products Administration, with 39 trials in Phase II or higher, indicating robust activity in drug development [8]. - The ongoing clinical trials for various drugs, including SKB500 for small cell lung cancer and Anladiwei for pediatric influenza, reflect the industry's focus on addressing unmet medical needs [14][12]. Regulatory Approvals - Four innovative drugs received approval during the week, including Yimazhi for pediatric Tourette syndrome and a radiopharmaceutical for prostate cancer detection [11]. - The approval of Anladiwei for adult treatment earlier this year and its subsequent pediatric trial initiation underscores the strategic expansion of product lines to meet market demands [13].

证券代码：002317 编号：2025-014 广东众生药业股份有限公司投资者关系活动记录表 | | √ □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 □路演活动 | | | □现场参观 □一对一沟通 | | | □其他（ ） | | 参与单位及人员 | 国泰海通证券股份有限公司、上海睿郡资产管理有限公司分 | | | 析师、研究员 | | 时间 | 2025 年 12 月 1 日 9:30～10:30 | | 地点 | 公司会议室 | | 形式 | 现场交流 | | 上市公司 | 1、公司董事会秘书 杨威 | | 接待人员 | 2、公司证券事务代表 陈子敏 | | | 1、公司昂拉地韦片有什么特色？ 答：昂拉地韦片是全球首款 RNA 聚合酶 PB2 靶点的甲型 流感口服药物，具有快速、强效、低耐药的特点，能够快速缓 | | | 解全身流感症状、强效抗击流感病毒，兼具低耐药性。 | | | 临床前研究结果表明，对包括奥司他韦耐药株、高致病性 | | 交流内容及具体 | 禽流感病毒株和玛巴洛沙韦耐药株等在内的多种不 ...

Investment Rating - The report does not explicitly state an investment rating for the industry [2] Core Views - The pharmaceutical and biotechnology sector saw a weekly increase of 2.67%, underperforming the Wind All A index (2.9%) but outperforming the CSI 300 index (1.64%). The raw material drug sector experienced a decline of 4.27%, while chemical preparations and pharmaceutical circulation products increased by 4.18% and 3.71%, respectively [3][8] - Recent policies in Shanghai and Beijing aim to support the high-quality development of the medical device industry, indicating a shift towards innovation and global competitiveness in this sector. The report suggests monitoring the transformation progress of leading companies in the medical device field [3][12] - Flu activity is on the rise, with the percentage of flu-like cases reported by sentinel hospitals in southern provinces reaching 7.8%, up from 6.8% the previous week, and higher than the same period in 2022 and 2024 [3][11] Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector increased by 2.67% from November 24 to November 28, 2025, with raw material drugs declining by 4.27% and chemical preparations increasing by 4.18% [8][9] - Individual stock performances included significant gains for Haiwang Biological (38.2%), Yue Wannianqing (36.2%), and Guangji Pharmaceutical (31.7%), while *ST Changyao (-15.3%), Huitai Medical (-9.6%), and Kangwei Century (-8.8%) saw notable declines [11] Industry News and Key Company Announcements Important Industry Events - The report highlights the increase in flu-like illness percentages in both southern (7.8%) and northern (8.6%) provinces, indicating a significant rise in flu activity compared to previous years [11][12] Industry News - Significant approvals were noted, including the NMPA's approval of Xinmeiyue® for treating moderate to severe plaque psoriasis and the FDA's accelerated approval of Sibeprenlimab for IgAN treatment [12][14] Company Announcements - Notable announcements include the FDA approval of a generic injectable drug by Jianyou Co. and the successful completion of a Phase III trial for JS001sc, a subcutaneous PD-1 monoclonal antibody for non-small cell lung cancer [15][16]

格隆汇11月26日丨众生药业(002317.SZ)在投资者互动平台表示，公司昂拉地韦颗粒III期临床试验正在 积极推进中。公司争取早日完成相关研究，申报药物上市，为广大患者提供更多治疗选择。 ...

| √ | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 □路演活动 | | | □现场参观 □一对一沟通 | | | □其他（ ） | | 参与单位及人员 | 中信建投证券股份有限公司、银华基金管理股份有限公司分 | | | 析师、研究员 | | 时间 | 2025 年 11 月 24 日 14:30～15:30 | | 地点 | 公司会议室 | | 形式 | 现场交流 | | 上市公司 | 1、公司董事会秘书 杨威 | | 接待人员 | 2、公司证券事务代表 陈子敏 1、公司昂拉地韦片有什么特色，是否对 H3N2 毒株有效？ | | | 答：昂拉地韦片是全球首款 RNA 聚合酶 PB2 靶点的甲型 流感口服药物，具有快速、强效、低耐药的特点，能够快速缓 | | | 解全身流感症状、强效抗击流感病毒，兼具低耐药性。 | | | 临床前研究结果表明，对包括奥司他韦耐药株、高致病性 | | 交流内容及具体 | 禽流感病毒株和巴洛沙韦耐药株等在内的多种不同亚型流感 | | 问答记录 | 病毒株具有强大的抑制活性。昂拉 ...

Group 1: Shareholding Changes - Guangli Micro plans to reduce its shareholding by up to 4.4062 million shares, accounting for 2.2359% of the total share capital after excluding repurchased shares [1] - Deepwater Haina intends to reduce its shareholding by up to 1% of the total share capital, which amounts to 177.28 million shares [1] Group 2: Pharmaceutical Developments - Baillie Tianheng's drug application for the first-in-class EGFR×HER3 dual antibody ADC (iza-bren) has been accepted for review by the National Medical Products Administration [2] - Zhongsheng Pharmaceutical has completed the first participant enrollment for the Phase III clinical trial of its innovative drug, Anladiwei granules, for treating influenza in children [2][3] Group 3: Financial Services - China Merchants Bank's wholly-owned subsidiary, China Merchants Jin Investment, has been approved to commence operations with a registered capital of 15 billion yuan [4] - CITIC Bank's wholly-owned subsidiary, Xinyin Jin Investment, has also received approval to start operations with a registered capital of 10 billion yuan [21] Group 4: Corporate Changes - Guiguan Network's chairman, Chen Yu, has resigned due to work changes, and Dai Qingsong has been nominated as the new chairman [5] - Caixin Development's controlling shareholder is undergoing bankruptcy restructuring, with uncertainties regarding the outcome and potential changes in control [6] Group 5: Industry Developments - JinkoSolar has achieved mass production of its new high-efficiency photovoltaic module "Tiger Neo 3.0," with a production efficiency exceeding 24.8% and a power output of 670W, securing 15GW in orders [8] - Ba Tian Co. has received approval for the safety facility design of its 2.9 million tons/year expansion project at the Xiaogaozai phosphate mine [10] Group 6: Strategic Collaborations and Acquisitions - Zhongding Co. has signed a strategic cooperation agreement with Fourier Intelligent Technology to collaborate on humanoid robot components [14] - Jinfu Technology is planning to acquire at least 51% of Guangdong Lanyuan Technology Co., Ltd. through cash payment [15] Group 7: Market Activities - Zhaowei Electric has received approval from the China Securities Regulatory Commission for its H-share issuance, planning to issue up to 69.0585 million H-shares [16] - Shanneng Electric has received registration approval for its private placement of shares from the China Securities Regulatory Commission [18]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002317 公告编号：2025-109 广东众生药业股份有限公司 关于控股子公司一类创新药昂拉地韦颗粒 III期临床试验完成首例参与者入组的公告 昂拉地韦片（商品名：安睿威?）是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药，适 用于成人单纯性甲型流感患者的治疗，具有快速、强效、低耐药等特点，于2025年5月获国家药监局批 准上市。同时，为满足青少年流感患者用药需求，公司补充开展了昂拉地韦片治疗12~17岁青少年单纯 性甲型流感患者的III期临床试验，在组长单位上海交通大学医学院附属瑞金医院PI指导下，目前参与者 入组情况顺利。 昂拉地韦颗粒是公司为方便儿童及吞咽困难的流感患者用药，开发的用于治疗甲型流感的一类创新药 物。昂拉地韦颗粒的II期临床试验结果表现出积极的疗效和良好的安全性，试验结果理想。在组长单位 首都医科大学附属北京儿童医院PI的指导下，公司于近日完成昂拉地韦颗粒III期临床试验的首例参与者 入组和给药。公司将继续按照相关要求高质量、加速度、科学规范地推进上述两项III期临床试验。 二、对公司的影响及风险提示 昂拉地韦颗粒 ...